Switching to Toujeo Reduced Hypoglycemia Risk in Older Patients

Researchers conducted a retrospective study of 1,610 senior adults with type 2 diabetes
Researchers conducted a retrospective study of 1,610 senior adults with type 2 diabetes

This article is part of MPR's coverage of the American Diabetes Association's 77th Scientific Sessions (ADA 2017), taking place in San Diego, CA. Our staff will report on medical research and technological advances in diabetes and diabetes education, conducted by experts in the field. Check back regularly for more news from ADA 2017.


Findings from a real-world observational study showed a significantly reduced risk of documented hypoglycemia after switching to Toujeo (insulin glargine 300 U/mL) vs. another basal insulin in older adults (aged ≥65 years) with type 2 diabetes. Data from the DELIVER 3 study were presented at the American Diabetes Association 77th Scientific Session, San Diego, CA.

DELIVER 3 was a retrospective, observational study (n=1,610) that used data from the Predictive Health Intelligence Environment (PHIE) database of real-world electronic medical records. Senior adults aged ≥65 years on basal insulin were switched to Toujeo or other basal insulins including Lantus (insulin glargine U100), Levemir (insulin detemir), and Tresiba (insulin degludec).

Study patients who switched to Toujeo were 57% less likely to have hypoglycemia at the 6-month follow-up (OR 0.432, 95% CI: 0.307–0.607; P<0.0001) vs. those who switched to another basal insulin. There were similar changes in HbA1c whether patients switched to Toujeo or  another basal insulin (least squares mean difference –0.09%; P=0.24).

The results from DELIVER 3 appeared consistent with that from DELIVER 2, a retrospective observational study that included two matched cohorts (n=3,654) of adults with type 2 diabetes taking basal insulin who switched to either Toujeo or another basal insulin. IN DELIVER 2, there were 33% less hypoglycemic events after 6 months in a bigger population group. Moreover, the Toujeo group exhibited significantly fewer all-cause hospital in-patient days, emergency department visits, and outpatient visits during the 6-month follow-up vs. patients who switched to another basal insulin. 

Toujeo, a long-acting insulin, is indicated to control blood sugar in adults with diabetes mellitus. It contains three times as much insulin per mL vs. standard insulin. It is available as 300 Units/mL strength in 3- or 5-count SoloStar prefilled pens.

For more information visit Toujeo.com.

Reference:
Zhou FL et al. Older Adults with Type 2 Diabetes (T2D) Experience Less Hypoglycemia When Switching to Insulin Glargine 300 U/mL (Gla-300) vs Other Basal Insulins (DELIVER 3 Study), Poster 986-P, American Diabetes Association (ADA) 77th Scientific Sessions, San Diego, CA, U.S., June 10, 2017.


Visit MPR's conference section for continuous coverage from ADA 2017